<table class="naaccr-summary-table naaccr-borders">
    <tr>
        <th class="naaccr-summary-header naaccr-borders">Item #</th>
        <th class="naaccr-summary-header naaccr-borders">Length</th>
        <th class="naaccr-summary-header naaccr-borders">Source of Standard</th>
        <th class="naaccr-summary-header naaccr-borders">Year Implemented</th>
        <th class="naaccr-summary-header naaccr-borders">Version Implemented</th>
        <th class="naaccr-summary-header naaccr-borders">Year Retired</th>
        <th class="naaccr-summary-header naaccr-borders">Version Retired</th>
        <th class="naaccr-summary-header naaccr-borders">Column #</th>
    </tr>
    <tr>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">1032</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">4</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">AJCC</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">1165 - 1168</td>
    </tr>
</table>

<br/><strong>NAACCR XML</strong>: Tumor.ajccTnmPathTSuffix<br/><br/>


<div class='content chap10-para-head'><strong><strong>Description</strong></strong></div>
<div class='content chap10-para'>Detailed site-specific codes for the pathological T category suffix as defined by AJCC.<br/><br/>Clinical, pathological, and postneoadjuvant therapy stage data are given three separate areas in the NAACCR Data Exchange Record Layout.
</div>
<div class='content chap10-para-head'><strong><strong>Rationale</strong></strong></div>
<div class='content chap10-para'>CoC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.</div>
<div class='content chap10-para'><strong>Codes (as published in the AJCC Cancer Staging Manual)</strong></div>
<div class='content chap10-para'>
    <table>
        <tr class='code-row'>
            <td class='code-nbr'>(m)</td>
            <td class='code-desc'>Multiple synchronous tumors
                OR
                For thyroid differentiated and anaplastic only, Multifocal tumor
            </td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'>(s)</td>
            <td class='code-desc'>For thyroid differentiated and anaplastic only, Solitary tumor</td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr'>Blank</td>
            <td class='code-desc'>No information available; not recorded</td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr' colspan='2'></td>
        </tr>
    </table>
</div>
<div class='content chap10-para'><em>Note</em>: Refer to the current AJCC Cancer Staging Manual for staging rules.</div>